AACR Project GENIE®

In November 2015, under the leadership of former AACR President Charles L. Sawyers, MD, FAACR, the AACR addressed this challenge by launching AACR Project GENIE® (Genomics Evidence Neoplasia Information Exchange)—an open-access, international, pan-cancer registry of real-world clinico-genomic data assembled through data sharing between 20 leading international cancer centers. AACR Project GENIE® pools the clinical sequencing efforts of its partner centers to accelerate drug discovery, improve clinical trial design, and drive progress for cancer patients globally.

Ten years after its launch, AACR Project GENIE® continues to provide a valuable evidence base for researchers worldwide. The consortium and its activities are driven by openness, transparency, and inclusion, ensuring that its output remains accessible and ultimately benefits patients everywhere.

In 2025, AACR Project GENIE® continued to deliver on the promise of precision medicine:

• Public Data Release. In July, Project GENIE shared its 18th public data release, expanding the registry to more than 211,000 patients. The release includes genomic and baseline clinical data from more than 250,000 tumors, which are accessible through the efforts of the project’s strategic and technical partners, Sage Bionetworks and cBioPortal.
• Community Engagement. AACR Project GENIE’s rich dataset continues to be a vital resource to the field; the registry was cited in more than 250 publications in 2025, which brings the total number of citations to more than 1,650 over the last 10 years.
• The AACR Annual Meeting 2025 highlighted new applications of the dataset, as users presented 27 proffered papers using Project GENIE data. The most compelling papers were again featured in a special Minisymposium titled, “Advancing Cancer Research Through an International Cancer Registry: AACR Project GENIE Use Cases. ”

• Read a summary of AACR Project GENIE® presentations from the AACR Annual Meeting 2025 on the AACR Blog, Cancer Research Catalyst

  
• Collaborative Research. In April, AACR Project GENIE® Steering Committee Chair Kenneth L. Kehl, MD, MPH, and coauthors published a comparative effectiveness study that used Project GENIE data to help evaluate larotrectinib in clinical trials versus standard of care in the real-world setting based on a study commissioned by Bayer Healthcare and Loxo Oncology, Inc.

• Larotrectinib Compared With Real-World Non–Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion Cancer
  
  Read this article featuring Project GENIE data in JCO Precision Oncology

  
• Biopharma Collective (BPC). Launched in 2019, the AACR Project GENIE® Biopharma Collective (BPC) is a collaboration with a coalition of 10 biopharmaceutical companies aimed to collect clinical and genomic data from an estimated 50,000 de-identified patients treated at Project GENIE participating institutions. The BPC has made substantial progress since its launch—with the completion of Phase 1 in 2021 and the expected completion of Phase 2 in 2026—and has made a wealth of resources available to the community, including public datasets featuring 1,846 non-small cell lung cancer patients, 1,485 colorectal cancer patients, and 1,129 early-onset breast cancer patients.
• Additional datasets featuring pancreatic cancer (1,100 patients), prostate cancer (1,100 patients), and bladder cancer (700 patients) will be available in early 2026.

• Collaborating Across Sectors in Service of Open Science, Precision Oncology, and Patients: An Overview of the AACR Project GENIE Biopharma Collaborative
  
  Read this Perspective in ESMO Real World Data and Digital Oncology

  

• Access the data available through the AACR Project GENIE Biopharma Collaborative release

  

Ten years after its launch, AACR Project GENIE® remains at the forefront of precision oncology. Moving forward, ongoing developments in the Biopharma Collaborative, new technological innovations, and increasing engagement from industry partners will ensure that Project GENIE continues to accelerate the pace of cancer discovery and clinical development for patient benefit.